Affiliations 

  • 1 Division of Cardiology, Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Selangor, Malaysia monmyat85@gmail.com
  • 2 Department of Medicine, Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia
  • 3 Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia
  • 4 Division of Cardiology, Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Selangor, Malaysia
  • 5 Division of Endocrinology, Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia
BMJ Open, 2021 01 21;11(1):e039869.
PMID: 33478961 DOI: 10.1136/bmjopen-2020-039869

Abstract

OBJECTIVE: To identify the prevalence of stage B heart failure (SBHF) in patients with type 2 diabetes mellitus (T2DM) with no history of cardiovascular disease (CVD).

DESIGN: Observational study.

SETTING: A single-centre study in which eligible patients were recruited from T2DM clinic. Following consent, patients completed a questionnaire and underwent physical examinations. Patients had blood drawn for laboratory investigations and had a transthoracic echocardiography.

PARTICIPANTS: A total of 305 patients who were not known to have CVD were recruited. Patients with deranged liver function tests and end stage renal failure were excluded.

MAIN OUTCOME MEASURES: Echocardiographic parameters such as left ventricular ejection fraction, left ventricular mass index (LVMI), left ventricular hypertrophy, left atrial enlargement and diastolic function were examined.

RESULTS: A total of 305 patients predominantly females (65%), with mean body mass index of 27.5 kg/m2 participated in this study. None of them had either a history or signs and symptoms of CVD. Seventy-seven percent of patients had a history of hypertension and 83% of this study population had T2DM for more than 10 years. Mean HbA1c of 8.3% was recorded. Almost all patients were taking metformin. Approximately, 40% of patients were on newer anti-T2DM agents such as sodium-glucose cotransporter-2 and dipeptidyl peptidase 4 inhibitors. Fifty-seven percent (n=174) of the study population had SBHF at the time of study: diastolic dysfunction, increased LVMI and increased left atrial volume index (LAVI) were noted in 51 patients (17%), 128 patients (42%) and 98 patients (32%), respectively. Thirty-seven patients (12%) had both increase LVMI and LAVI.

CONCLUSION: Our study has revealed a high prevalence of SBHF in T2DM patients without overt cardiac disease in Malaysia that has one of the highest prevalence of TDM in the world.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.